CollaGenex Pharmaceuticals, Inc. Release: Positive Results Of Phase 4 Clinical Study Evaluating Effects Of Oracea(TM) (doxycycline, USP) Capsules, 40 Mg, In Combination With MetroGel(R) (metronidazole gel), 1%, As Treatment For Rosacea Presented At Annual

NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced results of a Phase 4 clinical study designed to evaluate the efficacy of combining Oracea(TM) capsules and topical MetroGel in the treatment of rosacea. Study results were presented at the American Academy of Dermatology (AAD) Annual Meeting in Washington D.C. by the lead investigator, Joseph Fowler, MD, Clinical Professor of Dermatology, University of Louisville, Louisville, Kentucky. The trial also evaluated the effectiveness of Oracea for maintenance therapy in the treatment of rosacea.